Cited by 396Breast Cancer Treatment StudiesEstrogen and related hormone effectsAdvanced Breast Cancer Therapies

The DOI matches its Crossref record, with a small difference in title or year; 61 of the 61 references it cites were found in a registry or an index.

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Meta-analysis

Open access

Spring, Laura M., Gupta, Arjun, Reynolds, Kerry L., Gadd, Michele A., Ellisen, Leif W., Isakoff, Steven J., Moy, Beverly, Bardia, Aditya·2016·JAMA Oncology

DOI 10.1001/jamaoncol.2016.1897PMC PMC5738656

Open this paper in CoChat — free account

Abstract

IMPORTANCE: Estrogen receptor-positive (ER+) tumors of the breast are generally highly responsive to endocrine treatment. Although endocrine therapy is the mainstay of adjuvant treatment for ER+ breast cancer, the role of endocrine therapy in the neoadjuvant setting is unclear. OBJECTIVE: To evaluate the effect of neoadjuvant endocrine therapy (NET) on the response rate and the rate of breast conservation surgery (BCS) for ER+ breast cancer. DATA SOURCES: Based on PRISMA guidelines, a librarian-led search of PubMed and Ovid MEDLINE was performed to identify eligible trials published from inception to May 15, 2015. The search was performed in May 2015. STUDY SELECTION: Inclusion criteria were prospective, randomized, neoadjuvant clinical trials that reported response rates with at least 1 arm incorporating NET (n = 20). Two authors independently analyzed the studies for inclusion. DATA EXTRACTION AND SYNTHESIS: Pooled odds ratios (ORs), 95% CIs, and P values were estimated for end points using the fixed- and random-effects statistical model. RESULTS: The analysis included 20 studies with 3490 unique patients. Compared with combination chemotherapy, NET as monotherapy with aromatase inhibitors had a similar clinical response rate (OR, 1.08; 95% CI, 0.50-2.35; P = .85; n = 378), radiological response rate (OR, 1.38; 95% CI, 0.92-2.07; P = .12; n = 378), and BCS rate (OR, 0.65; 95% CI, 0.41-1.03; P = .07; n = 334) but with lower toxicity. Aromatase inhibitors were associated with a significantly higher clinical response rate (OR, 1.69; 95% CI, 1.36-2.10; P < .001; n = 1352), radiological response rate (OR, 1.49; 95% CI, 1.18-1.89; P < .001; n = 1418), and BCS rate (OR, 1.62; 95% CI, 1.24-2.12; P < .001; n = 918) compared with tamoxifen. Dual combination therapy with growth factor pathway inhibitors was associated with a higher radiological response rate (OR, 1.59; 95% CI, 1.04-2.43; P = .03; n = 355), but not clinical response rate (OR, 0.76; 95% CI, 0.54-1.07; P = .11; n = 537), compared with endocrine monotherapy. The incidence of pathologic complete response was low (<10%). CONCLUSIONS AND RELEVANCE: Neoadjuvant endocrine therapy, even as monotherapy, is associated with similar response rates as neoadjuvant combination chemotherapy but with significantly lower toxicity, suggesting that NET needs to be reconsidered as a potential option in the appropriate setting. Additional research is needed to develop rational NET combinations and predictive biomarkers to personalize the optimal neoadjuvant strategy for ER+ breast cancer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jamaoncol.2016.1897

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582
Statistical Aspects of the Analysis of Data From Retrospective Studies of Disease
(1959) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/22.4.719 · Cited by 14,689
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
Aspirin plus Clopidogrel as Secondary Prevention after Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2014) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,609
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
Cortazar, P., Zhang, L., Untch, M., Mehta, K. M., Costantino, J. P., Wolmark, N., Bonnefoi, H. R., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,777
Efficacy and Safety of Tadalafil Monotherapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Meta-Analysis
Dong, Y., Hao, L., Shi, Z., Wang, G., Zhang, Z., & Han, C. (2013) · Urologia Internationalis · doi:10.1159/000351405 · Cited by 4,557
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Howell, A., Cuzick, J. M., Baum, M., Buzdar, A. U., Dowsett, M., Forbes, J., Hoctin-Boes, G., Houghton, J., Locker, G. Y., & Tobias, J. S. (2005) · The Lancet · doi:10.1016/s0140-6736(04)17666-6 · Cited by 2,284
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900

Flagged first, then by citations

Show all 60 references

Research works printed but not linked: 1

[61]Ma CX Gao F Northfelt D A phase II trial of neoadjuvant palbociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, in combination with anastrozole for clinical stage 2 or 3 estrogen receptor positive HER2 negative (ER+HER2−) breast cancer (BC) Presented at: San Antonio Breast Cancer Symposium December 11, 2015 San Antonio, TX Abstract S6-05

Sorted by citations

Items 301–396 of 396

Cáncer de mama en la Clínica Internacional de Lima Metropolitana (2016-2021)
Aldecoa-Bedoya, F. (2022) · Interciencia médica · doi:10.56838/icmed.v12i3.102 · Cited by 1
Study protocol: Randomized, open-label, non-inferiority clinical trial for evaluating the clinical and pathological response rates to neoadjuvant hormone therapy and chemotherapy in patients with luminal-subtype breast tumors
Gouveia, M. C., Santos, C. L., & de Souza, A. I. (2022) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2022.101013 · Cited by 1
The use of neoadjuvant hormone therapy in locally advanced luminal breast cancer
Kochetkova, Y. I., Стенина, М. Б., Petrovsky, A. V., Титова, Т. А., Vishnevskaya, Y. V., & Frolova, M. A. (2024) · Practical oncology · doi:10.31917/2502136 · Cited by 1
The role of progesterone and estrogen receptors in treatment choice after endometriosis surgery: A cross-sectional study
Poordast, T., Alborzi, S., Kiani, Z., Omidifar, N., Askary, E., Chamanara, K., Shokripour, M., & Abadi, A. K. H. (2024) · International Journal of Reproductive BioMedicine (IJRM) · doi:10.18502/ijrm.v22i7.16970 · Cited by 1
Use of cyclin-dependent kinase 4 and 6 inhibitors in treating metastatic breast cancer - a year-long experience of Subotica General Hospital in patient follow-up
Zelen, T. B., Jovisevic, M., & Prica, A. (2024) · Medicinski pregled · doi:10.2298/mpns2404094b · Cited by 1
Characterization of breast cancer tumors in older patients who show de novo resistance to endocrine therapy
Ishizuka, Y., Horimoto, Y., Yuan, M., Ueki, Y., Onagi, H., Saeki, H., Hayashi, T., Saito, T., Kawate, T., Ishikawa, T., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-83895-2 · Cited by 1
Recent development in treatment strategies for breast cancer: With special reference to immunotherapy
Sharma, R., Tiwari, J. K., Kumari, P., Verma, S., Garg, V. K., Okpala, C. O. R., Buttar, H. S., & Kashyap, D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-24838-2.00008-2 · Cited by 1
Chemotherapy in Breast Cancer
Bhatia, K. P., & Batra, A. (2025) · Springer eBooks · doi:10.1007/978-981-97-9847-6_15 · Cited by 2
Efficacy of Dual Hormonal Therapy with Fulvestrant and Aromatase Inhibitors as Neoadjuvant Endocrine Treatment for Locally Advanced Breast Cancer
Majić, A., Bajić, Ž., Ban, M., Sedlar, I. T., Čerina, D., Miše, B. P., Strikić, A., Tomić, S., & Vrdoljak, E. (2025) · Cancers · doi:10.3390/cancers17132083 · Cited by 1
Nouvelle chirurgie du cancer du sein
Chauvet, M. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.08.020 · Cited by 1
Can cyclin-dependent kinase 4/6 inhibitors convert inoperable breast cancer relapse to operability? A case report
Palleschi, M., Maltoni, R., Barzotti, E., Melegari, E., Curcio, A., Cecconetto, L., Sarti, S., Manunta, S., & Rocca, A. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i3.517 · Cited by 1
ASO Author Reflections: Nodal Downstaging and Conversion to Breast-Conserving Surgery Following Neoadjuvant Endocrine Therapy
Montagna, G., Morrow, M., & Pilewskie, M. L. (2020) · Annals of Surgical Oncology · doi:10.1245/s10434-020-08971-z · Cited by 1
ASO Author Reflections: Tailoring Axillary Surgery After Neoadjuvant Endocrine Therapy for Breast Cancer
Kantor, O., & King, T. A. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09435-0 · Cited by 1
Running breast cancer services in the National Health Service during COVID-19 pandemic, single center experience
Elamin, G., Milburn, N., & Jahan, A. (2021) · Annals of Breast Surgery · doi:10.21037/abs-20-83 · Cited by 1
Neoadjuvant Systemic Therapy for Breast Cancer Based on Underlying Tumor Biology
Sikov, W. M. (2021) · Springer eBooks · doi:10.1007/978-3-030-88020-0_6 · Cited by 1
Systemic Therapy for Locally Advanced Breast Cancer
Keskın, S., & Aydıner, A. (2016) · Springer eBooks · doi:10.1007/978-3-319-26012-9_15 · Cited by 1
Prise en charge des cancers du sein infiltrants localisés : les nouveaux enjeux
Jankowski, C., Fumet, J.-D., Kaderbhai, C., Peignaux, K., Arnould, L., Ladoire, S., & Coutant, C. (2021) · Cited by 1
Neoadjuvant Hormonal Therapy in Breast Cancer
Mandel, N. M., & Selçukbırıcık, F. (2016) · Springer eBooks · doi:10.1007/978-3-319-26012-9_14
From Standard of Care to the Neoadjuvant Model as an Innovative Platform for Exploring Promising Combinations in Breast Cancer
Saura, C. (2018) · Breast Care · doi:10.1159/000492515
Neoadjuvant Treatment in Breast Cancer
Wang, R., & Dang, C. T. (2019) · Springer eBooks · doi:10.1007/978-3-319-62927-8_12
Molecular Mechanisms of Chemotherapy Resistance in Oestrogen Receptor Positive Breast Cancer
Baxter, D. E. (2019) · White Rose eTheses Online (University of Leeds, The University of Sheffield, University of York)
A Case Report of an 82-year-old Breast Cancer Patient who Achieved a Pathological Complete Response by Neoadjuvant Hormone Therapy
Haruka, A. S. A. I., Ogura, H., Takatsuka, D., ASANO, Y., Nakamura, A., & Norihiko, S. I. Y. A. (2019) · Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association) · doi:10.3919/jjsa.80.681
Use of Real-World Evidence in Hematology/Oncology Treatment Optimization
Vose, J. M. (2020) · ONCOLOGY · doi:10.46883/onc.2020.3411.0459
Opening Doors: Fertility Preservation for Adolescents and Young Adults Facing Gonadotoxic Therapy
Constance, E. S. (2020) · ONCOLOGY · doi:10.46883/onc.2020.3411.0500
Is breast surgery time critical when neo‐adjuvant therapy is not appropriate?
Wood, M. E. (2021) · The Breast Journal · doi:10.1111/tbj.14230
ASO Author Reflections: Objective Response Rate after Short Duration (< 9 Weeks) Is Not Inferior to Moderate (9–27 Weeks) or Long Duration (> 27 Weeks) of Neoadjuvant Endocrine Therapy (NET)—An NCDB Analysis
Burkbauer, L., Goldbach, M. M., & Tchou, J. C. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-10517-w
Locally Advanced Breast Cancer—A Narrative Review of Management in the Indian Scenario
Rao, M., & Dhanushkodi, M. (2021) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0041-1732785
Primary/Neoadjuvant Treatments
Mert, A. G., & Demir, O. G. (2021) · Springer eBooks · doi:10.1007/978-3-030-73147-2_16
Tratamiento del cáncer de mama infiltrante localizado: nuevos desafíos
Jankowski, C., Fumet, J.-D., Kaderbhaï, C., Peignaux, K., Arnould, L., Ladoire, S., & Coutant, C. (2021) · EMC - Ginecología-Obstetricia · doi:10.1016/s1283-081x(21)45718-8
ABSI – The Voice for Breast Surgery in India; Celebrating 10 positively eventful years! (2011 – 2021)
Pillarisetti, R. R., & Somashekhar, S. P. (2021) · Indian Journal of Surgery · doi:10.1007/s12262-021-03099-0
Surgical Considerations and Expectations in Patients Receiving Neoadjuvant Chemotherapy and Neoadjuvant Endocrine Therapy
Kantor, O., & Weiss, A. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-88020-0_11
Tumors: Breast
Geiss, R., Gattás-Vernaglia, I. F., & Brain, E. G. C. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_774
Role of Chemotherapy in Breast Cancer
Julka, P. K., Gupta, I., & Tiwari, R. (2022) · Springer eBooks · doi:10.1007/978-981-16-4546-4_20
Survival Comparison Between Adjuvant and Neoadjuvant Radiotherapy for Non-inflammatory Non-metastatic Breast CancerPreprint
Zhang, Y., Xu, Z., Chen, H., Sun, X., & Zhang, Z. (2022) · Research Square · doi:10.21203/rs.3.rs-1265365/v1
International Society of Gastrointestinal Oncology Conference Abstracts
Bekaii-Saab, T. (2020) · ONCOLOGY · doi:10.46883/onc.2020.3411.0468
From experiment to theory: What can we learn from growth curves?
Kareva, I., & Karev, G. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814368-1.00011-4
Tumors: Breast
Geiss, R., Gattás-Vernaglia, I. F., & Brain, E. G. C. (2020) · Springer eBooks · doi:10.1007/978-3-319-69892-2_774-1
Faculty Opinions recommendation of Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study.
Potter, D. A. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734060252.793581154
Neoadjuvant Hormonal Therapy in Breast Cancer
Mandel, N. M., & Selçukbırıcık, F. (2019) · Springer eBooks · doi:10.1007/978-3-030-16792-9_14
Promising Therapies Emerging for Recurrent/Metastatic Cervical Cancer
(2020) · ONCOLOGY · doi:10.46883/onc.2020.3411.0486
Bibliogrpahy
(2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814368-1.09992-6
Hitting a New Target in Multiple Myeloma
(2020) · ONCOLOGY · doi:10.46883/onc.2020.3411.0488
Systemic Therapy for Locally Advanced Breast Cancer
Keskın, S., & Aydıner, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-16792-9_15
Response Letter
Brezezinska, M., Williams, L. J., Thomas, J., & Dixon, J. M. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4368-4
Non-resectable Patients
Gal‐Yam, E. N., & Poortmans, P. M. (2022) · Springer eBooks · doi:10.1007/978-3-030-91170-6_47
Assessment of body mass index and its relationship with breast cancer survival in a clinical oncology service in the Federal District
Ferreira, K. F., Weis, L. N., Assunção, L. A., de Oliveira, E. S. C., & de Castro, R. A. (2022) · Brazilian Journal of Oncology · doi:10.5935/2526-8732.20220348
Data from Estrogen Receptor Pathway Activity Score to Predict Clinical Response or Resistance to Neoadjuvant Endocrine Therapy in Primary Breast Cancer
de Inda, M. A., Blok, E. J., Kuppen, P. J. K., Charehbili, A., den Biezen, E., van Brussel, A., Fruytier, S. E., Kranenbarg, E. M., Kloet, S. L., van der Burg, B., et al. (2023) · doi:10.1158/1535-7163.c.6539547.v1
A novel gene signature to predict response to neoadjuvant chemotherapy and endocrine treatment in estrogen receptor-positive breast cancer patientsPreprint
Sionakidis, A., Cannings, T. I., Figueroa, J. D., & Sims, A. H. (2023) · Research Square · doi:10.21203/rs.3.rs-2771576/v1
Effects of clinical treatment decisions on long-term survival outcomes of locally advanced breast cancer with different molecular subtypes based on the SEER databasePreprint
Fang, Q., Shen, H., Deng, C., Su, T., Chen, A., Hu, C., Liu, C., Xu, Y., Yang, Q., Hu, D., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3116105/v1
Applied Aspects of Systemic Therapy in Breast Oncoplasty and Reconstruction
Kirar, S., Gogia, A., & Deo, S. V. S. (2023) · Springer eBooks · doi:10.1007/978-981-99-5536-7_8
Receptor Positive Breast Lesions and Status of Axillary Lymph Node
Singhal, V. K. (2023) · Cureus · doi:10.7759/cureus.50645
Prolonged time to breast cancer surgery and the risk for metastasisPreprint
Hoelzel, D., Schlesinger‐Raab, A., Schubert-Fritschle, G., & Halfter, K. (2024) · medRxiv · doi:10.1101/2024.01.11.24301150
Efficacy of neoadjuvant endocrine therapy in HR-positive/HER2-negative breast cancer: A review
Abduloeva, N. K., Моисеенко, В., Moiseenko, F. V., Skripko, О. А., Scriabin, M. V., & Ryandjina, R. A. (2023) · Practical oncology · doi:10.31917/2404406
Genomic Testing to Guide Local Therapy Decisions in Hormone Receptor-Positive Breast Cancer
Lloyd, K., & Kantor, O. (2024) · Current Breast Cancer Reports · doi:10.1007/s12609-024-00538-1
Systemic Therapy for Breast Cancer
Hallmeyer, S., Qamar, R., & Shamah, C. J. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93249-3.00009-6
Effective Ki-67 Reduction by Short-Term Administration of Letrozole Before Surgery in (Hormone-Positive) Breast Cancer
Eslami, B., Alipour, S., Golfam, F., Jahanbin, B., & Omranipour, R. (2024) · Iranian journal of pathology · doi:10.30699/ijp.2023.2002772.3118
Exploring a Novel Approach to Spare Classic Chemotherapy in HER2-Low, ER-Positive Breast Cancer Based on Trastuzumab Deruxtecan Combined with Endocrine Therapy
Scafuri, L., Buonerba, C., Lauro, V. D., Tortora, V., Cascella, M., Liguori, L., Sciarra, A., Sabbatino, F., Diana, A., Marra, A., et al. (2024) · Oncology and Therapy · doi:10.1007/s40487-024-00286-3
Optimal management of breast cancer with physical exam negative/radiological abnormal axilla
Bi, Z., Li, L., Chen, P., Li, Z.-D., Qiu, P., & Wang, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-70874-w
Neoadjuvant therapy combined with surgical treatment for malignant tumors of the lower pharynx with lymph node involvement
Ren, W., Song, J.-Z., Huang, T., & Zhi, K.-Q. (2024) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2024.09.044
Breast Cancer
Moscol, G., Mitchell, M., & Hwang, R. F. (2024) · Cambridge University Press eBooks · doi:10.1017/9781009279864.014
Investigating the genetic causal relationship between breast cancer and endometrial cancer: A two-sample Mendelian randomization study
Wu, J., Xiao-bi, H., Lin, Y.-M., Zhang, Q., Chen, X.-R., Huang, Z., Ye, H., Xie, Y.-L., Yang, Z., Su, W., et al. (2024) · Medicine · doi:10.1097/md.0000000000040153
Management of Early and LABC Breast Cancer: Chemotherapy and Targeted Therapy in Breast Cancer
Bhatia, K. P., Fernandes, S., & Kumar, A. (2024) · Springer eBooks · doi:10.1007/978-981-97-7755-6_23
Neoadjuvant chemotherapy and hormonal therapy for locally advanced luminal HER2-negative breast cancer
Kochetkova, Y. I., Фролова, М. А., Stenina, M. B., Druzhinina, D. I., Titova, T. A., Жуликов, Я. А., Petrovsky, A. V., Vishnevskaya, Y. V., & Rumyantsev, A. A. (2025) · Medical alphabet · doi:10.33667/2078-5631-2024-32-34-39
Analysis of the Therapeutic Effect of TAC Regimen in Combination with Neoadjuvant Endocrine Therapy for HR-Positive/HER-2-Negative Breast Cancer
高, 尚. (2025) · Advances in Clinical Medicine · doi:10.12677/acm.2025.151188
Die ältere Patientin im Fokus der Senologie
Linz, V. C., Schmidt, M., & Hasenburg, A. (2025) · Die Gynäkologie · doi:10.1007/s00129-025-05348-9
Molecular Characterisation of the Residual Disease after Neoadjuvant Endocrine Therapy in Er+/Her2- Breast Cancer Uncovers Biomarkers of Tumour ResponsePreprint
López-Velazco, J. I., Manzano, S., Elorriaga, K., Otaño, M., Lahuerta, A., Álvarez, L., Etxabe, I., Huarte, M., Buch, E., Giménez, J., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5218750
Navigating Endocrine Sensitivity Assessment in Nonmetastatic Breast Cancer Through Early On-Treatment Ki67 Understanding
Paiva, C. E., Guimarães, V. S., Silva, A. T. F., Maia, Y. C. D. P., Paiva, B. S. R., Reinert, T., & LeVasseur, N. (2025) · Clinical Breast Cancer · doi:10.1016/j.clbc.2025.04.019
Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer
Beck, A. S., Earley, M. J., Troxell, M. L., Tsai, J., Telli, M. L., & Wapnir, I. (2025) · Breast Cancer Research and Treatment · doi:10.1007/s10549-025-07722-6
Niraparib Plus Aromatase Inhibitors for Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with a Germline BRCA Mutation
Lema, L., Pérez-García, J. M., Blanch, S., Balmañà, J., García-Sáenz, J. Á., Vegas, E. F., Jiménez, B., de la Haba-Rodríguez, J., Campolier, M., Shimizu, E., et al. (2025) · Cancers · doi:10.3390/cancers17111744
Integrative analysis of pre-treatment RNA expression signatures and recurrent genomic alterations: Link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancerPreprint
Zhang, G., Ni, H., Mishieva, L., Bartels, S., Christgen, M., Christgen, H., Kandt, L. D., Raap, M., Kates, R. E., Gluz, O., et al. (2025) · medRxiv · doi:10.1101/2025.06.11.25329354
Dual cutoffs of estrogen receptor positivity define prognostic and predictive subgroups in breast cancer
Takeshita, T., Iwase, H., Wu, R., Ishikawa, T., Yan, L., & Takabe, K. (2025) · iScience · doi:10.1016/j.isci.2025.114486
Additional file 1 of A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer
López-Velazco, J. I., Manzano, S., Otaño, M., Elorriaga, K., Bultó, N., Herrero, J. J., Lahuerta, A., Segur, V., Álvarez-López, I., Caffarel, M. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24940553
Additional file 1 of Acupuncture-related techniques for postoperative cognitive complications: a systemic review and meta-analysis
ZHANG, J., Cairen, Z., Shi, L., Zhang, M., Yang, M., Wang, Y., & Lu, Z. (2024) · Figshare · doi:10.6084/m9.figshare.26586570
Extending Eligibility for Breast Conserving Therapy: A Review of Emerging Indications and Techniques to Enable Breast Conservation
Beck, E. E., Dacier, B. M., Moore, E. A., Polakowski, N. L., Tonneson, J. E., & Rosenkranz, K. M. (2025) · Current Breast Cancer Reports · doi:10.1007/s12609-025-00627-9
Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Jin, P., Li, X. N., & Zhou, Y. (2025) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/ceog47264
Ensemble transformer-based multiple instance learning for predicting neoadjuvant chemotherapy response from breast cancer biopsy whole-slide images
Wu, Z., Ye, K., Weng, J., Zhang, Z., Liao, X., & Du, K. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1728511
Tumor and red blood cell fatty acid composition as a potential indicator of outcomes in breast cancer: Findings from a retrospective cohort study
Munhoz, J., Goruk, S., Mazurak, V. C., Ghosh, S., Hemmings, D. G., & Field, C. J. (2026) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2026.102733
Uncovering Gene Expression Patterns in Tamoxifen Response: A Computational Approach to Breast Cancer Treatment
Jindal, M., Jain, P., Sharma, A., Bhatia, S., & Jha, A. (2026) · Communications in computer and information science · doi:10.1007/978-3-032-19239-4_29
CDK4/6 inhibitors in invasive lobular carcinoma: Efficacy, resistance patterns, and endocrine partners
Khan, S. M., Jawwad, A., Kashif, M., Abbas, B., Kabir, S., Badar, A., Sheikh, H., Azam, A., & Khan, S. R. (2026) · Journal of Oncology Pharmacy Practice · doi:10.1177/10781552261434861
Neoadjuvante Therapie – Chancen der Therapieoptimierung
Gluz, O., Fischer, L. A., Bjelic‐Radisic, V., & Graeser, M. (2026) · Die Gynäkologie · doi:10.1007/s00129-026-05484-w
Current Update in Localisation and Management of Breast Cancer in Neoadjuvant Therapy
Wang, J., Malhotra, S., & Tadros, A. B. (2026) · Springer eBooks · doi:10.1007/978-3-032-17995-1_5
Survival outcomes after neoadjuvant chemotherapy in hormone receptor–positive breast cancer patients with nodal metastases: A National Cancer Database analysis
Bolourani, S., Diskin, B., Handy, N., Fancher, C. E., & Grumley, J. G. (2026) · Surgery · doi:10.1016/j.surg.2026.110236
Ensemble Transformer-Based Multiple Instance Learning for Predicting Neoadjuvant Chemotherapy Response from Breast Cancer Biopsy Whole-Slide Images
Du, K., Ye, K., Wu, Z., Chen, B., Hong, J., Zhang, Z., Dai, Y., & Liao, X. (2026) · Lecture notes in computer science · doi:10.1007/978-981-95-7141-3_28
Complete Cell Cycle Arrest of Hormone Receptor–Positive Bilateral Breast Cancer with Neoadjuvant Abemaciclib plus Letrozole: A Case Report and Review of Literature
Singh, K., Valame, S. N., Manek, D. D., Mehrotra, N., Gupta, V., Jain, R., & Azad, S. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1824458
Tracking Utilization of Neoadjuvant Endocrine Therapy (NET) and Neoadjuvant Chemotherapy (NCT) for Hormone Receptor-Positive Breast Cancer (HR + BC) in the U.S.A. Over Time – A TriNetX Database Study
Lim, J. K., Gibson, A. E., He, J., Antonucci, A., & Bear, H. D. (2026) · Clinical Breast Cancer · doi:10.1016/j.clbc.2026.05.008
Axillary Management After Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer
Gu, Z., Zhang, Y. H., Ye, Y., & Qian, W. (2026) · Clinical Breast Cancer · doi:10.1016/j.clbc.2026.06.011
Current Comprehensive Management of Breast Cancer: Review of Literature
Sm, B., & Kaushik, R. (2026) · Haryana Journal of Surgery · doi:10.4103/hjs.hjs_5_26
Can neoadjuvant endocrine therapy de-escalate surgery in luminal breast cancer? A four-year retrospective study from a single referral center
Skulimowski, A., Skórniak, J., Michalik, T., Ekiert, M., Skulimowska, K., Kasprzak, P., & Matkowski, R. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1831764
Ultrasound‐Derived Nomogram for Differentiating HER2 +/ HER2 − Subtypes in Luminal B‐Type Breast cancer: Principal Ultrasound Determinants and Model Validation
Zhang, S., Ren, T., Tong, Y., Han, Y., & Cheng, W. (2026) · Journal of Clinical Ultrasound · doi:10.1002/jcu.70353
Efficacy and Safety of Neoadjuvant Chemotherapy Followed by CDK4 /6 Inhibitors Plus Endocrine Therapy in Patients With HR ‐Positive, HER2 ‐Negative Breast Cancer: A Retrospective Single‐Centre Cohort Analysis
Dong, X., Li, F., Yuan, Y., Song, H., Wang, Y., Hao, Y., Dong, Y., Wang, T., Bian, L., Zhang, S., et al. (2026) · Cancer Medicine · doi:10.1002/cam4.72258
The role of CDK4/6 inhibitors in the treatment of luminal HER2/neu-negative early breast cancer
Potselueva, P. D., Физулиевна, Е. С., & Kornietskaya, A. L. (2026) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2026-258
Modern Models of Breast Cancer: Integration of Molecular Biological Approaches for Study of Signaling Pathways and Development of Therapies
Kadyrova, A. S., Rizvanov, A. A., & Solovyeva, V. V. (2026) · Molecular Biology · doi:10.1134/s0026893326700159
Targeting Aromatase and HDACs in Hormone Receptor-Positive Breast Cancer: Molecular Interplay, Endocrine Resistance and Therapeutic Opportunities
Lucaciu, R. L., Hangan, A. C., Oprean, L. S., & Procopciuc, L. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27198619
Treatment of Breast Cancer
Ruddy, K. J., Idossa, D. W., Black, D. M., Corbin, K. S., Cathcart-Rake, E. J., & O'Sullivan, C. C. (2026) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2026.07.019 · Cited by 1
The challenge of evaluating the efficacy of neoadjuvant endocrine therapy in breast cancer and potential solutions: a literature review
Dzhelyalova, M. A. D., Золотухина, А. Е., Шалаев, А. В., Донских, Р. В., Криворотько, П. В., & Malek, A. V. (2026) · Medical alphabet · doi:10.33667/2078-5631-2026-15-26-34
BindingDB Entry 50022488: Are all cyclin-dependent kinases 4/6 inhibitors created equal?
BindingDB (2025) · UC San Diego · doi:10.7270/q2zw1rn8

Authors: Spring, L. M., Gupta, A., Reynolds, K. L., Gadd, M. A., Ellisen, L. W., Isakoff, S. J., Moy, B., & Bardia, A.
Affiliations: Harvard University (US)
The University of Texas Southwestern Medical Center (US)
Corresponding author: Bardia, Aditya
ORCID: Spring, Laura M.
Gupta, Arjun
Reynolds, Kerry L.
Ellisen, Leif W.
Isakoff, Steven J.
Moy, Beverly
Bardia, Aditya
Venue: JAMA Oncology
Publisher: American Medical Association (AMA)
Published: 2016-11-01
Volume: 2
Issue: 11
Pages: 1477
ISSN: 2374-2437 (ISSN-L)
DOI: 10.1001/jamaoncol.2016.1897
PMC: PMC5738656
OpenAlex: W2467606258
Cited by: 396
References: 60
Citations by year: 2026: 28 · 2025: 52 · 2024: 48 · 2023: 36 · 2022: 48 · 2021: 56 · 2020: 63 · 2019: 26 · 2018: 13 · 2017: 18 · 2016: 8
FWCI: 9.03
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: JAMA Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR001102)
National Cancer Institute (K12CA087723, T32CA071345)
National Center for Advancing Translational Sciences
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: neoadjuvant endocrine therapy, estrogen receptor-positive breast cancer, aromatase inhibitors, breast-conserving surgery, clinical response rate, combination chemotherapy, treatment toxicity, randomized controlled trials meta-analysis
MeSH terms: Breast Neoplasms, Female, Humans, Receptors, Estrogen, Randomized Controlled Trials as Topic, Treatment Outcome, Chemotherapy, Adjuvant, Antineoplastic Agents, Hormonal, Neoadjuvant Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Neoadjuvant Endocrine Therapy for Estrogen Receptor–Positive Breast Cancer: A Systematic Review and Meta-analysis

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks